{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:05:52Z","timestamp":1788300352803,"version":"build-2803163510"},"reference-count":21,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1253\/circj.cj-16-1310","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T18:12:42Z","timestamp":1495476762000},"page":"1496-1505","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Bococizumab (RN316\/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin\/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive\u3000\u2015 Results From a Randomized, Placebo-Controlled, Dose-Ranging Study \u2015"],"prefix":"10.1253","volume":"81","author":[{"given":"Koutaro","family":"Yokote","sequence":"first","affiliation":[{"name":"Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kanada","sequence":"additional","affiliation":[{"name":"Heishinkai Medical Group Incorporated"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"ToCROM Clinic, Heishinkai Medical Group Incorporated"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakuni","family":"Sekino","sequence":"additional","affiliation":[{"name":"Sekino Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Imai","sequence":"additional","affiliation":[{"name":"Development Japan, Pfizer Japan Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tabira","sequence":"additional","affiliation":[{"name":"Development Japan, Pfizer Japan Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobushige","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Development Japan, Pfizer Japan Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Worldwide Research and Development, Pfizer Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Teikyo Academic Research Center, Teikyo University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Okamura T. Dyslipidemia and cardiovascular disease: A series of epidemiologic studies in Japanese populations. <i>J Epidemiol<\/i> 2010; 20: 259\u2013265.","DOI":"10.2188\/jea.JE20100060"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Absolute risk of cardiovascular disease and lipid management targets. <i>J Atheroscler Thromb<\/i> 2013; 20: 689\u2013697.","DOI":"10.5551\/jat.17392"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. <i>Lancet<\/i> 2010; 376: 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, et al. Proprotein convertase substilisin\/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. <i>J Pharmacol Exp Ther<\/i> 2012; 340: 228\u2013236.","DOI":"10.1124\/jpet.111.187419"},{"key":"5","unstructured":"5. Gumbiner B, Udata C, Joh T, Liang H, Wan H, Shelton DL, et al. The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin (abstract). <i>Circulation<\/i> 2012; 126: A13322."},{"key":"6","unstructured":"6. Gumbiner B, Joh T, Udata C, Forgues P, Baum CM, Garzone PD. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2 delta a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high and maximal dose statins (abstract). <i>Circulation<\/i> 2012; 126: 2782."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. <i>Am J Cardiol<\/i> 2015; 115: 1212\u20131221.","DOI":"10.1016\/j.amjcard.2015.02.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wang EQ, Plowchalk D, Gibiansky L, Sweeney K, Kaila N. Population pharmacokinetic and pharmacodynamic modeling of bococizumab (RN316\/PF-04950615) in hypercholesterolemic subjects (abstract). <i>Atherosclerosis<\/i> 2014; 235: e262.","DOI":"10.1016\/j.atherosclerosis.2014.05.786"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. <i>J Lipid Res<\/i> 2008; 49: 394\u2013398.","DOI":"10.1194\/jlr.M700437-JLR200"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. <i>J Lipid Res<\/i> 2010; 51: 2714\u20132721.","DOI":"10.1194\/jlr.M008144"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <i>Am Heart J<\/i> 2016; 178: 135\u2013144.","DOI":"10.1016\/j.ahj.2016.05.010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. <i>N Engl J Med<\/i> 2017; 376: 1517\u20131526.","DOI":"10.1056\/NEJMoa1614062"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. <i>N Engl J Med<\/i> 2017; 376: 1527\u20131539.","DOI":"10.1056\/NEJMoa1701488"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. <i>Ann Intern Med<\/i> 2015; 163: 40\u201351.","DOI":"10.7326\/M14-2957"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: Primary results from the Phase 2 YUKAWA study. <i>Circ J<\/i> 2014; 78: 1073\u20131082.","DOI":"10.1253\/circj.CJ-14-0130"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. <i>Am J Cardiol<\/i> 2016; 117: 40\u201347.","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, et al. Efficacy and safety of alirocumab in Japanese subjects (Phase 1 and 2 studies). <i>Am J Cardiol<\/i> 2016; 118: 56\u201363.","DOI":"10.1016\/j.amjcard.2016.04.011"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins: ODYSSEY JAPAN randomized controlled trial. <i>Circ J<\/i> 2016; 80: 1980\u20131987.","DOI":"10.1253\/circj.CJ-16-0387"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Teramoto T, Kashiwagi A, Ishibashi S, Daida H. Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: Clinical impact of combination therapy with ezetimibe. <i>Curr Ther Res Clin Exp<\/i> 2012; 73: 1\u201315.","DOI":"10.1016\/j.curtheres.2012.02.001"},{"key":"20","unstructured":"20. Pfizer Inc. Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor [press release]; November 1, 2016. http:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor (accessed April 5, 2017)."},{"key":"21","unstructured":"21. World Health Organization. The top 10 causes of death. http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/ (accessed April 5, 2017)."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/81\/10\/81_CJ-16-1310\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T19:03:37Z","timestamp":1569351817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/81\/10\/81_CJ-16-1310\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-16-1310","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}